Document:

EX-10.5

 Exhibit 10.5 

Horizon Therapeutics Public Limited Company 

Non-Employee Director Compensation Policy 

Amended Effective: May 1, 2019 
 Each
member of the Board of Directors (the “Board”) of Horizon Therapeutics Public Limited Company (the “Company”) other than (1) any member who
is affiliated with any holder of more than 5% of the Company’s ordinary shares or (2) any member serving as an employee of the Company or any of its subsidiaries (each such member, a
“Director”) will receive the following compensation for his or her Board service. The determination of whether a member of the Board meets the requirements to be eligible to receive compensation as
an eligible Director under this Policy will be determined as of the date such cash compensation is otherwise payable, or the date such equity compensation would be granted, as applicable. 

Annual Cash Compensation 
 The annual cash compensation
amount set forth below is payable in equal quarterly installments, payable in arrears on the last day of each fiscal quarter in which the service occurred. If a Director joins the Board at a time other than effective as of the first day of a fiscal
quarter, each annual retainer/fee set forth below will be pro-rated based on days served in the applicable fiscal year, with the pro-rated amount paid for the first
fiscal quarter in which the Director provides the service, and regular full quarterly payments thereafter. All annual cash fees are vested upon payment. 
  

	1.	 Annual Board Service Retainer: 

 

	 	a.	 Non-Executive Chairman of the Board/Lead Independent Director: $100,000

  

	 	b.	 All other Directors: $60,000 

 

	2.	 Annual Committee Chair Service Fee: 

 

	 	a.	 Chairman of the Audit Committee: $30,000 

 

	 	b.	 Chairman of the Compensation Committee: $20,000 

 

	 	c.	 Chairman of the Nominating & Corporate Governance Committee: $15,000 

 

	 	d.	 Chairman of the Transaction Committee: $20,000 

 

	3.	 Annual Committee Member (non-Chair) Service Fee:

  

	 	a.	 Audit Committee: $15,000 

 

	 	b.	 Compensation Committee: $10,000 

 

	 	c.	 Nominating & Corporate Governance Committee: $7,500 

 

	 	d.	 Transaction Committee: $12,500 

Equity Compensation 
 The equity compensation set forth
below will be granted under the Horizon Therapeutics Public Limited Company 2014 Non-Employee Equity Plan, as may be amended from time to time (the “Plan”). 

  
 1 

 1. Initial Grant: On the date of any Director’s initial appointment or election to the Board,
the Director will be automatically, and without further action by the Board, granted restricted stock units with an aggregate value equal to $400,000, prorated based on the number days between such Director’s start date and the first
anniversary of the date of the annual shareholder meeting of the Company that most recently preceded such start date (the “Initial Grant”); provided, that if a Director’s initial election to the Board occurs at an
annual shareholder meeting of the Company, such Director will receive only the Annual Grant (as defined below) for such annual shareholder meeting and not a separate Initial Grant. The restricted stock units will vest in full upon the earlier of the
(i) first anniversary of the date of the annual shareholder meeting of the Company that most recently preceded such Director’s start date and (ii) date of the next annual shareholder meeting of the Company, subject to the
Director’s Continuous Service (as defined in the Plan) through such vesting date. A Director who, in the one year prior to his or her initial election to serve on the Board as a non-employee director,
served as an employee of the Company or one of its subsidiaries will not be eligible for an Initial Grant. 
 2. Annual Grant: On the date of each
annual shareholder meeting of the Company, each Director will be automatically, and without further action by the Board, granted restricted stock units with an aggregate value of $400,000 (the “Annual Grant”). The restricted
stock units will vest in full upon the earlier of the (i) first anniversary of the date of grant and (ii) date of the next annual shareholder meeting of the Company, subject to the Director’s Continuous Service through such vesting
date. 
 Expenses 
 The Company will reimburse each
Director for ordinary, necessary and reasonable out-of-pocket travel expenses to cover in-person attendance at and participation
in Board and/or Committee meetings; provided, that Directors timely submit to the Company appropriate documentation substantiating such expenses. In addition, the Company will reimburse each Director up to $15,000 annually for financial
counseling services, including (1) personal financial planning, (2) estate planning and (3) preparation of tax returns and tax planning for the Directors and/or their dependent children. 

  
 2EX-10.6

 Exhibit 10.6 
  

			
		  	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE HORIZON THERAPEUTICS PLC HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE
HARM TO HORIZON THERAPEUTICS PLC IF PUBLICLY DISCLOSED.

 CONFIDENTIAL 

AMENDMENT NO. 1 TO 

COMMERCIAL SUPPLY AGREEMENT 
 This
Amendment No. 1 (the “Amendment”) to the Commercial Supply Agreement by and between Horizon Pharma Ireland Limited (“Customer”) and AGC Biologics A/S, formerly known as CMC Biologics A/S
(“AGC”) is dated as of May 15, 2019 (“Amendment Effective Date”). 
 RECITALS 

AGC and Customer are Parties to the Commercial Supply Agreement effective as of February 14, 2018 (the “Agreement”). AGC and Customer
wish to amend certain provisions of the Agreement so that AGC may subcontract certain Services to AGC’s affiliated entity, AGC Biologics, Inc., located in Bothell, Washington (“AGC SEA”). 

AGREEMENT 
 1. Definition and
Interpretation. The definition of “AGC Facility” in Clause 1.1 of the Agreement is deleted in its entirety and replaced by the following: 

“AGC Facility” means AGC’s manufacturing facility in Copenhagen, Denmark, Bothell, Washington or another AGC facility agreed on in
writing by the Parties. 
 2. Quality Agreement. The following provision is added to the end of Clause 2.3: 

Promptly following the Amendment Effective Date, but in any event within [***] days following the Amendment Effective Date unless mutually extended by
the Parties, AGC and Customer shall execute an addendum to the Commercial Quality Agreement or enter into a new Quality Agreement to address the manufacture of Product by AGC SEA. 

3. Subcontract to Affiliates. Clause 2.5.1 is deleted in its entirety and replaced with the following: 

2.5 AGC may subcontract 
 2.5.1 to its Affiliates, specifically
AGC SEA, any part of the Services (provided that the Affiliates may not further subcontract those parts of the Services), with the prior written consent of Customer (such consent not to be unreasonably withheld, delayed or conditioned); 

4. Subcontract to Testing Laboratories. Pursuant to Clause 2.5.2 of the Agreement, Customer acknowledges and agrees that AGC SEA
may subcontract the Services identified in the definition of Testing Laboratories to the parties identified as Contract Labs on Attachment C to the Commercial Quality Agreement. 

5. Customer Materials; AGC Materials. Clause 3.1 of the Agreement is deleted in its entirety and replaced with the following: 

All Raw Materials purchased by AGC for the Services will be the property of AGC. Customer will reimburse AGC for any Raw Materials purchased and consumed by
AGC for manufacture of Product. Payments made by Customer to reimburse AGC for Raw Materials purchased for the Services shall be 
 [***] =
CERTAIN CONFIDENTIAL INFORMATION OMITTED 

  
 1 

 CONFIDENTIAL 

deemed advance payments for Product (“Advance Payments”). Title to Product shall pass to Customer as set out in Clauses
6.3 and 6.7 of this Agreement. 
 6. Invoicing and Payment Terms. Clauses 7.4, and 7.5 and
7.8 of the Agreement are deleted in their entirety and replaced with the following: 
 7.4 Unless otherwise agreed to in writing by
the Parties, all invoices will be in Euros and Customer agrees to pay all sums due hereunder in Euros and shall be issued to Horizon from the AGC Facility in Copenhagen, Denmark. 

7.5 Unless otherwise agreed to in writing by the Parties, AGC will issue invoices in accordance with the provisions of Appendix Two. 

7.8 Advance Payments and shipping costs for all Services will be invoiced to Customer as set forth in Appendix Two. 

7. Appendix Two. Appendix Two to the Agreement is deleted in its entirety and replaced with Appendix Two to this Amendment No. 1.

 8. No Other Amendment; Confirmation. Except as expressly amended, modified and supplemented by this Amendment No. 1, the
provisions of the Agreement, including the provisions of Clause 6.16 and Appendix Two, shall remain in full force and effect. Unless otherwise defined in this Amendment No. 1, all capitalized terms used but not defined in this Amendment
No. 1 shall have the meaning set forth in the Agreement. Each Party acknowledges that it has read this Amendment No. 1, understands the changes affecting the Agreement and agrees to be bound by the terms of the Agreement as modified by
this Amendment No. 1. The Parties further acknowledge and agree that the Agreement, as amended, embodies the complete and exclusive understanding among the Parties and supersedes and merges all related prior proposals and understandings whether
oral or written. 
 IN WITNESS WHEREOF, the Parties have executed this Amendment effective as of the Amendment Effective Date. 

 

							
	HORIZON PHARMA IRELAND LIMITED	 	 AGC BIOLOGICS A/S, formerly known as

CMC Biologics A/S

				
	By	 	 /s/ Alan Mac Neice 
	 	By	  	 /s/ Patricio Massera 

	Print Name	 	Alan Mac Neice	 	Print Name	  	Patricio Massera
	Title	 	 Director
	 	Title	  	 CEO

		 	duly authorized	 		  	duly authorized

  
 2 

 CONFIDENTIAL 

APPENDIX TWO 
  

	
	 [***]

 [***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED 

 

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00298-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00298-of-00352.parquet"}]]